Compare MLCO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLCO | RCUS |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2006 | 2018 |
| Metric | MLCO | RCUS |
|---|---|---|
| Price | $8.85 | $25.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $10.08 | ★ $28.88 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $5,061,044,000.00 | $240,000,000.00 |
| Revenue This Year | $13.64 | N/A |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | $34.27 | ★ N/A |
| Revenue Growth | ★ 11.46 | N/A |
| 52 Week Low | $4.55 | $6.50 |
| 52 Week High | $10.15 | $26.40 |
| Indicator | MLCO | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 76.50 |
| Support Level | $8.74 | $24.32 |
| Resistance Level | $9.53 | $26.40 |
| Average True Range (ATR) | 0.34 | 1.29 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 37.74 | 89.51 |
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.